The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Open accessThe DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Ten male patients with well-regulated type 2 diabetes (A1C 6.9 ± 0.8%, age 56 ± 10 years, BMI 31 ± 3 kg/m2 [means ± SD]) were subjected to five 120-min glucose clamps at fasting plasma glucose (FPG) levels. On day 1, GLP-1 was infused to stimulate endogenous insulin release and suppress endogenous glucagon. On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and glucagon (no glucagon suppression or insulin stimulation); day 3, basal insulin only (glucagon deficiency); day 4, basal glucagon and stimulated insulin; and day 5, stimulated insulin. The basal plasma glucagon levels were chosen to simulate portal glucagon levels. RESULTS: Peptide infusions produced the desired hormone levels. The amount of glucose required to clamp FPG was 24.5 ± 4.1 (day 1), 0.3 ± 0.2 (day 2), 10.6 ± 1.1 (day 3), 11.5 ± 2.7 (day 4), and 24.5 ± 2.6 g (day 5) (day 2 was lower than days 3 and 4, which were both similar and lower than days 1 and 5). CONCLUSIONS: We concluded that insulin stimulation (day 4) and glucagon inhibition (day 3) contribute equally to the effect of GLP-1 on glucose turnover in patients with type 2 diabetes, and these changes explain the glucose-lowering effect of GLP-1 (day 5 vs. day 1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Considering the prominent role of adipose tissue in energy homeostasis59,172, it is plausible that GIPR agonism in fat could harness beneficial effects on metabolic homeostasis.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [59]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“We employed the pancreatic clamp technique (11) using somatostatin to block the endogenous secretion from the islets while substituting insulin and/or glucagon levels by infusions designed to mimic either basal levels and/or responses to a GLP-1 infusion rate (1 pmol/kg/min) known to normalize blood glucose in patient…”
BackgroundMethodSelf-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The assay reacts equally with intact GLP-1 and with GLP-1 (9–36) amide, the primary metabolite (16).”
MethodSelf-citationGlucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 1×
“Since in humans the target of glucagon action is the liver (18,19), which is exposed to portal glucagon levels, we chose the portal levels; these were successfully reached (in peripheral plasma) during the glucagon infusions.”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Despite their hyperglycemia, patients with type 2 diabetes tend to have elevated fasting glucagon levels and exaggerated glucagon responses to meal ingestion (5).”
BackgroundSelf-citation共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Cited by
Items 201–275 of 275
Pinheiro, M. M., Pinheiro, F. M. M., Garo, M. L., Pastore, D., Pacifici, F., Ricordi, C., Della‐Morte, D., & Infante, M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.12 · Cited by 11
Kochis, M. A., Bizimana, C., Zitsman, J. L., Pratt, J. S. A., & Griggs, C. L. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.05.045 · Cited by 8
Ugi, S., Yamamoto, H., 楠知里, Kamo, A., Ikeda, K., Hashimoto, T., Nishio, Y., Kasama, K., Tani, T., Kashiwagi, A., et al. (2010) · Diabetology International · doi:10.1007/s13340-010-0011-x · Cited by 8
“Furthermore, the recent report has shown that suppression of glucagon secretion and stimulation of insulin secretion contribute equally to the glucoselowering action of GLP-1 [16].”
BackgroundGraham, G. V., McCloskey, A. G., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110584 · Cited by 10
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
Singh‐Franco, D. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1004311 · Cited by 12
“Other plausible effects of GLP-1 that contribute to glucose lowering include suppression of glucagon secretion in islet a-cells [8], delayed gastric emptying [9,10] and induction of satiety (FIGURE 1A) [7,11].”
BackgroundLiu, J., Sun, Y., Zheng, H., Wang, J., Liu, L., Song, B., & Zhang, H. (2021) · BioMed Research International · doi:10.1155/2021/6662704 · Cited by 9
“Therefore, it plays an important role in blood glucose homeostasis [18].”
BackgroundAlpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Klempel, N., Thomas, K. G., Conlon, J. M., Flatt, P. R., & Irwin, N. (2022) · Peptides · doi:10.1016/j.peptides.2022.170877 · Cited by 7
“However, administration of glucagon promotes weight loss, an important factor in reversing insulin resistance, by increasing energy expenditure and lipid catabolism, suggesting a possible therapeutic role in the management of obesity-related type 2 diabetes mellitus (T2DM) [12].”
InfluentialGraham, G. V., Conlon, J. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173101 · Cited by 7
“Glucagon-like peptide-1 (GLP-1) stimulates insulin release as well as supressing both glucagon release and appetite and promoting proliferation of ß-cells (Hare et al., 2010; Dailey and Moran, 2013; Drucker, 2018).”
BackgroundResultEffectiveness of sitagliptin in a patient with late dumping syndrome after total gastrectomy
Kurihara, K., Tamai, A., Yoshida, Y., Yakushiji, Y., Ueno, H., Fukumoto, M., & Hosoi, M. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.11.001 · Cited by 5
Liu, C., Xu, H., Yuan, F., Chen, H., Sheng, L., Chen, W., Xie, H., Xu, H., & Li, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326865 · Cited by 4
Current pharmacotherapy options for type 2 diabetes
Habtemariam, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102922-0.00005-5 · Cited by 7
Total synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling
Lin, N.-P., & Chein, R. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01722a · Cited by 4
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Advances in clinical research on glucagon
Horie, I., & Abiru, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00705-w · Cited by 3
“After the recent introduction of incretin mimetics/enhancers, it was demonstrated that an inhibition of glucagon secretion contributed to lower glucose levels in patients with T2D treated with glucagon-like peptide-1 (GLP-1) receptor agonists [72] or dipeptidyl peptidase-4 inhibitors [73].”
Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
“GIGD negatively correlated with the AUC-glucagon in OGTT, suggesting that GIGD re fl ects the role of glucagon in glucose excursions (20, 52, 53).”
BackgroundMethodAn alternative combination therapy for type 2 diabetes?
Østoft, S. H., & Christensen, M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60615-8 · Cited by 3
Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C. H., Grøndahl, M. F. G., Deacon, C. F., Hartmann, B., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13321 · Cited by 4
Self-citationFukui, H., Mizuguchi, H., Kitamura, Y., & Takeda, N. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_255 · Cited by 4
Hanna, A., Woo, V. C., Yale, J., & Cooke, E. M. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.01.005 · Cited by 5
Katsuno, T., Ikeda, H., & Namba, M. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0170-2 · Cited by 3
“Dipeptidyl peptidase-4 inhibitors have both a glucose-dependent insulinotropic effect and a glucagonostatic effect, which contribute equally to the glucose-lowering action of these drugs [11].”
BackgroundPhysiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822122 · Cited by 3
Williams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
Ismail, R. (2020) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10468 · Cited by 5
Qin, Y., Zhang, W., Zhang, H., Li, Y., Huang, W.-Q., Xie, J., Yang, S., Li, L., Cui, C., Pei, Q., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2500303 · Cited by 2
“…weight management, and cardio-vascular health [6] GLP-1 RAs control blood glucose levels by reducing food intake, delaying gastric emptying, enhancing insulin secretion, and suppressing glucagon release, while maintaining efficacy under both hyperglycemic and euglycemic conditions [7,8].”
GPR41 and GPR43 modulate rodent pancreatic α-cell function and growth
Sánchez-Roncero, A., Fernández‐Marcelo, T., Perez-Serna, A. A., Martín, M. Á., Alberquilla, O., Sánchez‐Domínguez, R., Segovia, J. C., Escrivá, F., Gálvez, B. G., Álvarez, C., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123913 · Cited by 2
Assessment of Islet Alpha- and Beta-Cell Function
Madsbad, S., & Holst, J. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_2 · Cited by 4
Self-citationPreoperative Patient Evaluation
Villasenor, M., & Selzer, A. R. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.08.004 · Cited by 2
Honka, H., Gastaldelli, A., Pezzica, S., Peterson, R. E., DeFronzo, R. A., & Salehi, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15570 · Cited by 2
Hormones and Hormones Antagonists
Kaur, A., Chakraverty, R., & Mathur, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-2776-6_9 · Cited by 3
Fu, L., Sugiyama, M., Kamal, S., Ide, T., Takeda, T., Kuno, M., Takagi, H., Koike, T., Arima, H., & Banno, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104595 · Cited by 4
Agonistas del receptor de GLP-1
Huamán, H. C. A. (2020) · Diagnóstico · doi:10.33734/diagnostico.v59i2.219 · Cited by 4
Nouvelles voies thérapeutiques du diabète de type 2 ciblées sur le glucagon et son récepteur
Moller, D. E., KAZDA, C. M., & Cueille, C. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70208-5 · Cited by 2
Efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes switched from glinides
Tanaka, T., Goto, H., Araki, R., Yamamoto, M., Tanaka, T., Fujiwara, R., & Murata, K. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12140 · Cited by 2
L’étrange histoire du glucagon
Schlienger, J.-L. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30183-3 · Cited by 2
Ito, K., Satoh, S., Kondo, Y., Tamura, H., Hasebe, M., & Terauchi, Y. (2022) · Diabetology International · doi:10.1007/s13340-022-00592-z · Cited by 1
Role of glucagon in treating diabetes: Evidence and concepts (胰高血糖素在糖尿病治疗中的作用:证据与概念)
Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12107 · Cited by 1
Vaciamiento gástrico y Diabetes mellitus tipo 2
Cadavid, C. A. Q., Regino, W. O., & Vega, R. F. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n2.46195 · Cited by 2
Behary, P., Godsland, I. F., & Baynes, K. (2014) · Practical Diabetes · doi:10.1002/pdi.1867 · Cited by 2
Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog
Edgerton, D. S., An, Z., Johnson, K., Farmer, T. E., Farmer, B., Neal, D. W., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00160.2013 · Cited by 2
Enteral Nutrition and Glucagon-Like Peptide-1 in Intensive Care Unit Patients
Bakıner, O., & Ertörer, M. E. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8503-2_146-1 · Cited by 1
Sharma, S. B. (2016) · Journal of Diabetes and Obesity · doi:10.15436/2376-0494.16.864 · Cited by 1
PANCREATIC ALPHA CELL DYSFUNCTION IN DIABETES MELLITUS AND ITS MANAGEMENT STRATEGIES
Pradhan, B., & Majhi, C. (2017) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2017/551 · Cited by 2
Enteral Nutrition and Glucagon-Like Peptide-1 in Intensive Care Unit Patients
Bakıner, O., & Ertörer, M. E. (2015) · Springer eBooks · doi:10.1007/978-1-4614-7836-2_146 · Cited by 1
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Kawamura, M., Hariya, N., Ishiyama, S., Tanaka, Y., Ozato, K., & Mochizuki, K. (2024) · Nutrition · doi:10.1016/j.nut.2024.112656 · Cited by 1
Hashimoto, K.-I., Horikawa, Y., & Takeda, J. (2015) · Diabetology International · doi:10.1007/s13340-015-0219-x · Cited by 1
“While the glucagonostatic and insulinotropic effects of GLP-1 have been reported to contribute equally to its glucose-lowering action in middle-aged obese Europeans with type2 diabetes [21], we show in this study that the complementary glucagonostatic and insulinotropic effects of the DPP-4 inhibitors in reducing post…”
BackgroundKorani, M. A., & Sonbol, A. A. (2018) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_76_17 · Cited by 1
Levels of Glucagon-like Peptide 1 are Decreased in Macrosomic Neonates from Non-Diabetic Mothers
Aktulay, A., Üstün, Y. E., Gündüz, Ö., Yılmaz, C., Erkaya, S., & Ozgu-Erdinc, A. S. (2018) · Zeitschrift für Geburtshilfe und Neonatologie · doi:10.1055/a-0660-9734 · Cited by 1
Double et triple agonistes : rôle du glucagon
Scheen, A. J. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.006 · Cited by 2
Inhibition de la sécrétion du glucagon par les agonistes du GLP-1 et les inhibiteurs de la DPP-4
Hansen, M. V., Knop, F. K., Hare, K. J., & Holst, J. J. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70207-3 · Cited by 1
Self-citationHonka, H., Gastaldelli, A., Pezzica, S., Peterson, R. E., DeFronzo, R. A., & Salehi, M. (2023) · medRxiv · doi:10.1101/2023.09.20.23295840 · Cited by 1
“primarily by increasing insulin secretion and suppressing glucagon secretion [1] in a glucose-”
BackgroundMyokardiale Regeneration im Glukagon-like-peptide-1 Rezeptor knock out Mausmodell
Ebner, S. (2015) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.18266
Carr, R. D., & Alexander, C. M. (2014) · Diabetes Care · doi:10.2337/dc14-0352
“Based on a study using native GLP-1 (3), it has been proposed that glucagon suppression and insulin secretion contribute equally to the blood glucose–lowering effect of DPP-4”
MethodInfluentialMerchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
“Interestingly, the glucagonostatic effects of GLP-1 are as important as its insulinotropic effects in improving glucose control in patients with type 2 diabetes 20 (Hare et al., 2010).”
BackgroundIshihara, H. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.3237
Blundell, J. E., Axelsen, M. B., Brooks, A., Flint, A., Kvist, T., Bergan, E. Q., & Hjerpsted, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(16)31220-7 · Cited by 1
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
Self-citationBahrami, J. (2011) · TSpace (University of Toronto)
Targeting the intestinal L-cell for obesity and type 2
Wewer, N. J., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2014)
Self-citationGlucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Ingenuos y generosos socialismos
Muru, V. M. A. (1976) · El Ciervo: revista mensual de pensamiento y cultura
Regional Intestinal Drug Absorption
Gonzalez-Alvarez, M. I., & Dahan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3657-6
Williams, J. A. (2021) · doi:10.3998/panc.2021.06
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationNon‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Self-citationSØRUM, N. E., Magnussen, T., Hansen, N. L., Nielsen, C. K., Holst, J. J., Hartmann, B., Henriksen, K., Størling, J., Faber, J., Christensen, M. B., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf215 · Cited by 1
“In addition, both GLP-1 and GIP exert effects on pancreatic α cells; with GIP stimulating glucagon secretion during normal to low plasma glucose concentrations [6, 7] and GLP-1 inhibiting secretion during high plasma glucose concentrations [8-10].”
Self-citationTherapeutic effect and underlying mechanism of emodin on renal injury
Mitra, P., Jana, S., Modak, B. S., & Roy, S. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100757
Dépôts de graisse ectopique : étude de leur développement et de leur modulation
Abdesselam, I. (2016) · theses.fr (ABES) · doi:10.70675/1f016024z175cz4b35z8034za3b418cfe9c3 · Cited by 1
Lobato, C. B., Nielsen, A. B. E., & Holst, J. J. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2025
Self-citationDepression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
Krogh, L. S. L., Hansen, M. B., Bergmann, N. C., Hansen, C. P., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A., & Gasbjerg, L. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70940 · Cited by 1
Self-citationSurgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Raval, K., Ilegems, E., Title, A. C., Fishburn, E., Bhardwaj, G., Mirguet, O., Ratcliffe, P. D., Greeff, O. B. W., van Wyk, A., & Tudzarova, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.20.752954 · Cited by 1
Metadata
- Authors
- Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-07-01
- Volume
- 59
- Issue
- 7
- Pages
- 1765-1770
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2889777
- OpenAlex
- W2117402345
- Cited by
- 276
- References
- 34
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 17 · 2023: 19 · 2022: 13 · 2021: 18 · 2020: 20 · 2019: 24 · 2018: 13 · 2017: 15 · 2016: 19 · 2015: 20 · 2014: 20 · 2013: 19 · 2012: 16
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucagon inhibition, insulin secretion, glucose-lowering effect, alpha cells, pancreatic beta cells, somatostatin, glucose turnover, insulin replacement therapy
- MeSH terms
- Insulin Secretion, Adult, Analysis of Variance, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Insulin, Male, Middle Aged, Time Factors, Glucose Clamp Technique, Treatment Outcome, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.